It hasn't been the best quarter for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) shareholders, since the share price has fallen 28% in that time. On the bright side the share price is up over the last half decade. In that time, it is up 53%, which isn't bad, but is below the market return of 90%. Unfortunately not all shareholders will have held it for the long term, so spare a thought for those caught in the 38% decline over the last twelve months.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

See our latest analysis for Syndax Pharmaceuticals

Syndax Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

For the last half decade, Syndax Pharmaceuticals can boast revenue growth at a rate of 6.2% per year. That's a pretty good long term growth rate. While the share price has gained 9% per year for five years, that's hardly amazing considering the market also rose. You could even argue that the share price was over optimistic, previously.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

Syndax Pharmaceuticals is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. You can see what analysts are predicting for Syndax Pharmaceuticals in this interactive graph of future profit estimates.

A Different Perspective

While the broader market gained around 25% in the last year, Syndax Pharmaceuticals shareholders lost 38%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 9% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Syndax Pharmaceuticals better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Syndax Pharmaceuticals .

But note: Syndax Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.